Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
IVISense MMP 750 FAST Fluorescent Probe (MMPSense)
IVISense MMP 750 FAST Fluorescent Probe (MMPSense)
Matrix metalloproteinases (MMPs) are calcium-dependent zinc containing endopeptidases responsible for the degradation of most of extracellular matrix proteins during organogenesis, growth and normal tissue turnover. MMPs play a role in almost every biological cell process from embryo implantation to cell death and have been implicated in a wide range of diseases including inflammation, arthritis, pulmonary disease, cancer and more.
Revvity’s IVISense™ MMP NIR activatable fluorescence probes (MMPSense®) are designed to evaluate many disease related processes including cancer progression, rheumatoid arthritis, pulmonary disease and more as well as evaluating therapeutic efficacy of potential drug candidates.
| Feature | Specification |
|---|---|
| Unit Size | 1 vial (10 doses) |
| Specificity | Matrix Metalloprotease |
Matrix metalloproteinases (MMPs) are calcium-dependent zinc containing endopeptidases responsible for the degradation of most of extracellular matrix proteins during organogenesis, growth and normal tissue turnover. MMPs play a role in almost every biological cell process from embryo implantation to cell death and have been implicated in a wide range of diseases including inflammation, arthritis, pulmonary disease, cancer and more.
Revvity’s IVISense™ MMP NIR activatable fluorescence probes (MMPSense®) are designed to evaluate many disease related processes including cancer progression, rheumatoid arthritis, pulmonary disease and more as well as evaluating therapeutic efficacy of potential drug candidates.
IVISense MMP 750 FAST Fluorescent Probe (MMPSense)
IVISense MMP 750 FAST Fluorescent Probe (MMPSense)
Product information
Overview
IVISense MMP 750 FAST is excited by 749 nm excitation light, and emits at 775 nm. MMP 750 FAST is a member of a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that allows for an earlier optimal imaging window of 12-24 hours after injection, facilitating detection of MMP activity changes in acute models of inflammation or stroke. In addition, the 750 nm wavelength is optimal for minimizing the impact of autofluorescence and chow-related fluorescence that can interfere with image quality. Including IVISense MMP 750 FAST in careful experimental design allows for multiplexing with other channels and/or imaging times, and so can be paired with other probes to achieve maximum efficiency and flexibility in imaging.
Specifications
| Brand |
IVISense
|
|---|---|
| Fluorescent Agent Type |
Enzyme activated
|
| Imaging Modality |
Fluorescence
|
| Shipping Conditions |
Shipped in Blue Ice
|
| Specificity |
Matrix Metalloprotease
|
| Storage Conditions |
-30 to -16 °C
|
| Therapeutic Area |
Arthritis
Atherosclerosis
Cardiovascular
Inflammation
Oncology
Pulmonary
Vascular
|
| Unit Size |
1 vial (10 doses)
|
| Wave Length |
750 nm
|
Resources
Are you looking for resources, click on the resource type to explore further.
MMPSense 750 FAST activatable fluorescent imaging agent protocol
Loading...
How can we help you?
We are here to answer your questions.
